Head-to-head
Semaglutide vs 5-Amino-1MQ
A field-by-field comparison of Semaglutide and 5-Amino-1MQ drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. Both are indexed as metabolic compounds, so the useful question is how they differ within that category.
Semaglutide vs 5-Amino-1MQ at a glance
| Attribute | Semaglutide | 5-Amino-1MQ |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence grade | Strong | Limited |
| Also known as | Ozempic, Wegovy | 5-amino-1-methylquinolinium |
| Chain | GLP-1 analogue, 94% homology to human GLP-1 | Small molecule (not strictly a peptide) |
| Mechanism | Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing. | Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Blocking it raises intracellular NAD+ and SAM, increasing energy expenditure in fat cells. |
| Reported benefits | ~15% mean body-weight reduction over 68 weeks in STEP-1 · Improved HbA1c and cardiovascular outcomes · Marked reduction in appetite and food noise | Reduced fat-cell size in rodent studies · Increased cellular NAD+ · Oral bioavailability — no injections |
| Reported side effects | Nausea and vomiting · Constipation or diarrhoea · Gallbladder issues · Contraindicated with medullary thyroid carcinoma history | Insomnia if dosed late · Mild GI upset · Unknown long-term profile |
| Half-life | About 7 days | Estimated several hours |
| Administration | Once-weekly subcutaneous injection (oral tablet also approved) | Oral capsule |
| Dosing overview | Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks | 50–150 mg once daily in the morning |
| Storage | Refrigerate 2–8 °C; in-use pens may be kept at room temperature per label | Cool, dry place away from light |
| Legal status | FDA-approved and prescription-only. | Sold as a research compound; not an approved drug or dietary supplement. |
Key differences between Semaglutide and 5-Amino-1MQ
Both are metabolic compounds
Semaglutide and 5-Amino-1MQ are both indexed under metabolic, so they compete for the same use case rather than complementing each other. Semaglutide: "A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market." 5-Amino-1MQ: "An orally active NNMT inhibitor grouped with metabolic peptides, studied for fat-cell metabolism and NAD+ preservation."
Mechanism of action
Semaglutide: Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing. 5-Amino-1MQ: Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Blocking it raises intracellular NAD+ and SAM, increasing energy expenditure in fat cells.
Evidence quality is not equal
Semaglutide carries a Strong evidence grade and 5-Amino-1MQ a Limited grade on this index. The grade describes the quality of published human data, not how well a compound works — Semaglutide has the better-documented record of the two, and claims made about 5-Amino-1MQ rest on thinner human evidence.
Half-life and dosing frequency
Semaglutide is listed at about 7 days; 5-Amino-1MQ at estimated several hours. That difference is what drives the reported schedules: Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks versus 50–150 mg once daily in the morning
Route of administration
Semaglutide is administered by once-weekly subcutaneous injection (oral tablet also approved). 5-Amino-1MQ is administered by oral capsule.
Legal and regulatory status differs
Semaglutide: FDA-approved and prescription-only. 5-Amino-1MQ: Sold as a research compound; not an approved drug or dietary supplement. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
Semaglutide is stored refrigerate 2–8 °c; in-use pens may be kept at room temperature per label. 5-Amino-1MQ is stored cool, dry place away from light.
What Semaglutide and 5-Amino-1MQ have in common
- Category: both listed as Metabolic
Each compound in brief
Semaglutide
Metabolic · Strong evidence
A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market.
Considerations: Muscle loss can account for a meaningful share of weight lost — resistance training and protein intake matter · GI side effects are dose-dependent; titrate slowly · Weight regain is common after stopping
5-Amino-1MQ
Metabolic · Limited evidence
An orally active NNMT inhibitor grouped with metabolic peptides, studied for fat-cell metabolism and NAD+ preservation.
Considerations: No published human trials · Often stacked with metabolic peptides · Marketed heavily ahead of the evidence
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.